Anebulo is a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid overdose and substance addiction. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within one hour of administration. Clinical trials completed to date have shown that ANEB-001 is rapidly absorbed, well-tolerated, and leads to weight loss, an effect that is consistent with central cannabinoid receptor type 1 antagonism.
Partial Data by Infogroup (c) 2024. All rights reserved.